TY - JOUR
T1 - What was old is new again
T2 - Using the host response to diagnose infectious disease
AU - Ko, Emily R.
AU - Yang, William E.
AU - McClain, Micah T.
AU - Woods, Christopher W.
AU - Ginsburg, Geoffrey S.
AU - Tsalik, Ephraim L.
N1 - Funding Information:
E Tsalik has received funding from NIAID, The Henry Jackson Foundation and Novartis. E Tsalik also has pending patents for infectious disease diagnostics. G Ginsburg has received funding from DARPA, NIAID, The Henry Jackson Foundation and Novartis. G Ginsburg has pending patents for infectious disease diagnostics. C Woods has received funding from DARPA, NIAID, The Henry Jackson Foundation and Novartis. C Woods has relationships with Novartis Diagnostics, BioFire, bioMerieux and Nanosphere, including research grants and advisory positions. C Woods has pending patents for infectious disease diagnostics. M McClain has received a grant from Veteran’ s Affairs Center, number 1IK2CX000611 (MTM). M McClain has pending patents for infectious disease diagnostics. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2015 © Informa UK, Ltd.
PY - 2015/9/2
Y1 - 2015/9/2
N2 - A century of advances in infectious disease diagnosis and treatment changed the face of medicine. However, challenges continue to develop including multi-drug resistance, globalization that increases pandemic risks and high mortality from severe infections. These challenges can be mitigated through improved diagnostics, focusing on both pathogen discovery and the host response. Here, we review how omics technologies improve sepsis diagnosis, early pathogen identification and personalize therapy. Such host response diagnostics are possible due to the confluence of advanced laboratory techniques (e.g., transcriptomics, metabolomics, proteomics) along with advanced mathematical modeling such as machine learning techniques. The road ahead is promising, but obstacles remain before the impact of such advanced diagnostic modalities is felt at the bedside.
AB - A century of advances in infectious disease diagnosis and treatment changed the face of medicine. However, challenges continue to develop including multi-drug resistance, globalization that increases pandemic risks and high mortality from severe infections. These challenges can be mitigated through improved diagnostics, focusing on both pathogen discovery and the host response. Here, we review how omics technologies improve sepsis diagnosis, early pathogen identification and personalize therapy. Such host response diagnostics are possible due to the confluence of advanced laboratory techniques (e.g., transcriptomics, metabolomics, proteomics) along with advanced mathematical modeling such as machine learning techniques. The road ahead is promising, but obstacles remain before the impact of such advanced diagnostic modalities is felt at the bedside.
KW - communicable diseases
KW - early diagnosis
KW - host-pathogen interactions
KW - metabolome
KW - molecular diagnostics
KW - proteome
KW - respiratory tract infection
KW - sepsis
KW - transcriptome
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=84940490759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940490759&partnerID=8YFLogxK
U2 - 10.1586/14737159.2015.1059278
DO - 10.1586/14737159.2015.1059278
M3 - Review article
C2 - 26145249
AN - SCOPUS:84940490759
VL - 15
SP - 1143
EP - 1158
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 9
ER -